Cordis Acquires Flexible Stenting Solutions, Inc.

Tue Mar 12, 2013 9:11am EDT

* Reuters is not responsible for the content in this press release.

Agreement Expands Treatment Options for Advanced Peripheral Artery Disease
BRIDGEWATER, N.J.--(Business Wire)--
Cordis Corporation, a worldwide leader in the development of interventional
vascular technology, today announced it has completed the acquisition of
Flexible Stenting Solutions, Inc., a leading developer of innovative flexible
peripheral arterial, venous and biliary stents. 

Currently, Cordis markets the S.M.A.R.T.® Vascular Stent worldwide. The addition
of Flexible Stenting Solutions` FlexStent® Self Expanding Stent System provides
Cordis with the opportunity to evolve the S.M.A.R.T.® Stent platform to address
unmet needs in the treatment of peripheral artery disease (PAD). It also extends
the company`s potential to expand therapeutic applications into below-the-knee
and venous interventions. An estimated 27 million people in Europe and North
America alone suffer from PAD. 

"Cordis continues to identify opportunities to enhance its expanding portfolio
of less invasive treatment options to address the needs of patients suffering
from vascular disease worldwide," said Shlomi Nachman, Company Group Chairman,
Cordis Corporation. "This acquisition will enable Cordis to provide clinicians
more options to meet their evolving therapeutic needs and to strengthen our
leadership position in the treatment of vascular disease." 

This acquisition marks another milestone in the company`s strategy to strengthen
its position in the endovascular market. Recently Cordis received superficial
femoral artery (SFA) and proximal popliteal artery (PPA) indications for the
S.M.A.R.T.® Stent, the only stent approved in the U.S. for iliac, SFA and PPA
vascular indications. In addition, Cordis offers market-leading endovascular
technology platforms including percutaneous transluminal angioplasty balloons
and chronic total occlusion crossing devices. 

"The FlexStent® System is a promising platform designed to optimize flexibility,
fracture resistance and radial strength with predictable placement. We look
forward to expanding our experience with this new technology platform," said
Prof. Dr. Thomas Zeller, Director Department Angiology at
Universitaets-Herzzentrum, Freiburg - Bad Krozingen, Bad Krozingen, Germany. 

The FlexStent® System received European CE Mark approval for the treatment of
vascular disease (iliac, SFA and popliteal) in January 2009. In the U.S., the
device received 510(k) clearance by the Food and Drug Administration (FDA) for
the palliative treatment of biliary strictures associated with malignant tumors
in September 2009. The FlexStent® System is also being evaluated in an
Investigational Device Exemption (IDE) study to evaluate its safety and efficacy
in the treatment of patients with atherosclerosis in the SFA, or SFA disease. 1
Data from the OPEN Trial are expected to support a Premarket Approval (PMA)
application requesting an expanded indication to treat SFA disease in the U.S. 

"We are pleased to have the opportunity to learn more about the FlexStent®
System technology and its potential therapeutic applications for patients in the
U.S. beyond currently approved indications," said William A. Gray, MD, Director
of Endovascular Services, Cardiovascular Research Foundation, New York. 

Terms of the acquisition were not disclosed. Dr. Gray and Prof. Dr. Thomas
Zeller are compensated for their services as consultants to Cordis. 

About Peripheral Artery Disease

Peripheral artery disease (PAD) is caused by the build-up of fatty substances
that collect and adhere to the linings of the arteries, in a process known as
atherosclerosis. The build-up causes the internal lining of the artery to
thicken, narrowing the artery and limiting blood flow to vital tissues and
organs. Commonly affected arteries include those located in the legs, arms, neck
and kidneys. 

About Cordis Corporation

Cordis Corporation, part of the Johnson & Johnson family of companies, is a
worldwide leader in the development and manufacture of interventional vascular
technology. Through the company's innovation, research and development, Cordis
partners with physicians worldwide to treat millions of patients who suffer from
vascular disease. More information about Cordis Corporation can be found at 

1. The FlexStent® System is approved for investigational use only in the United
States for the treatment of patients with atherosclerosis in the SFA, or SFA
disease. This product is not available for commercial sale in the United States
for this investigational use. The FlexStent® System is available for commercial
sale in the United States for the palliative treatment of biliary strictures
associated with malignant tumors pursuant to the 510(k) clearance received in
September 2009. 

This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not to
rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could vary materially
from the expectations and projections of Cordis Corporation and/or Johnson &
Johnson. Risks and uncertainties include, but are not limited to, general
industry conditions and competition; economic factors, such as interest rate and
currency exchange rate fluctuations; technological advances, new products and
patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; challenges to patents; changes in
behavior and spending patterns or financial distress of purchasers of health
care products and services; changes to governmental laws and regulations and
domestic and foreign health care reforms; trends toward health care cost
containment; increased scrutiny of the health care industry by government
agencies; manufacturing difficulties or delays; and product efficacy or safety
concerns resulting in product recalls or regulatory action. A further list and
description of these risks, uncertainties and other factors can be found in
Exhibit 99 of Johnson & Johnson`s Annual Report on Form 10-K for the fiscal year
ended December 30, 2012. Copies of this Form 10-K, as well as subsequent
filings, are available online at, or on request from
Johnson & Johnson. Neither Cordis Corporation nor Johnson & Johnson undertake to
update any forward-looking statements as a result of new information or future
events or developments.

Cordis Corporation
Sandy Pound
908-218-2720 office
908-432-2829 mobile

Copyright Business Wire 2013